European Union -
English -
EMA (European Medicines Agency)
jcovden (previously covid-19 vaccine janssen)
janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaccines - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older.the use of this vaccine should be in accordance with official recommendations.
European Union -
English -
EMA (European Medicines Agency)
vaxzevria (previously covid-19 vaccine astrazeneca)
astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaccines - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older.the use of this vaccine should be in accordance with official recommendations.
Canada -
English -
Health Canada
vaxzevria solution
astrazeneca canada inc - chadox1-s [recombinant] - solution - 50000000000vp - chadox1-s [recombinant] 50000000000vp
Canada -
English -
Health Canada
vaxzevria solution
astrazeneca canada inc - chadox1-s [recombinant] - solution - 50000000000vp - chadox1-s [recombinant] 50000000000vp
Canada -
English -
Health Canada
covishield solution
verity pharmaceuticals inc. - chadox1-s [recombinant] - solution - 50000000000vp - chadox1-s [recombinant] 50000000000vp
Canada -
English -
Health Canada
jcovden suspension
janssen inc - ad26.cov2.s [recombinant] - suspension - 50000000000vp - ad26.cov2.s [recombinant] 50000000000vp